As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of darolutamide for treating non-metastatic hormone-relapsed prostate cancer .
Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-January 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.